Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Regulus Therapeutics Inc shares valued at $17,359 were sold by Hagan Joseph P on Jan 18 ’24. At $1.19 per share, Hagan Joseph P sold 14,580 shares. The insider’s holdings dropped to 57,112 shares worth approximately $0.16 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, CALSADA CRISPINA sold 5,468 shares, netting a total of over 6,510 in proceeds. Following the sale of shares at $1.19 each, the insider now holds 5,782 shares.
Before that, Aker Christopher Ray had sold 5,468 shares from its account. In a trade valued at $6,510, the Sr. VP & General Counsel traded Regulus Therapeutics Inc shares for $1.19 each. Upon closing the transaction, the insider’s holdings decreased to 5,468 shares, worth approximately $28961.28.
As published in their initiating research note from Leerink Partners on March 18, 2024, Regulus Therapeutics Inc [RGLS] has been an Outperform and the price target has been revised to $6. Analysts at B. Riley FBR Inc. started covering the stock with ‘”a Neutral”‘ outlook in a report released in late March. As of January 05, 2018, Leerink Partners has initiated its “an Outperform” rating for RGLS. Earlier on June 13, 2017, Chardan Capital Markets resumed its rating. Their recommendation was “a Buy” for RGLS stock.
Analyzing RGLS Stock Performance
During the last five days, there has been a surge of approximately 15.20%. Over the course of the year, Regulus Therapeutics Inc shares have jumped approximately 125.00%. Shares of the company reached a 52-week high of $3.79 on 03/12/24 and a 52-week low of $1.08 on 01/17/24. A 50-day SMA is recorded $1.67, while a 200-day SMA reached $1.46. Nevertheless, trading volume fell to 0.89 million shares from 1.08 million shares the previous day.
Support And Resistance Levels for Regulus Therapeutics Inc (RGLS)
According to the 24-hour chart, there is a support level at 2.74, which, if violated, would cause prices to drop to 2.60. In the upper region, resistance lies at 3.01. The next price resistance is at 3.14. RSI (Relative Strength Index) is 75.92 on the 14-day chart, showing overbought technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.46, which suggests the price will decrease in the coming days. Percent R is at 36.84%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
Is Regulus Therapeutics Inc subject to short interest?
Stocks of Regulus Therapeutics Inc saw a sharp rise in short interest on Mar 15, 2024 jumping by 5.03 million shares to 5.13 million. Data from Yahoo Finance shows that the short interest on Feb 15, 2024 was 97000.0 shares. A jump of 98.11% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 0.6 of the overall float, the days-to-cover ratio (short ratio) jumped to 0.6.
